bevacizumab

Home
Ligands
bevacizumab

Ligand id: 6771

Name: bevacizumab

Classification
Compound class	Antibody
Approved drug?	Yes (FDA (2004), EMA (2005))

International Nonproprietary Names
INN number	INN
8017	bevacizumab

Synonyms
Avastin® \| rhuMAb-VEGF

Synonyms

Avastin® | rhuMAb-VEGF

Comments
Vascular endothelial growth factor A inhibitor. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Biosimilars: Bevacizumab-awwb (Mvasi®, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers. Pfizer's biosimilar (PF-06439535, trade name Zirabev®) received EMA marketing authorisation in April 2019, indicated for specified colorectal, breast, renal, lung, and cervical cancers. SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882). CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.

Comments

Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Bevacizumab-awwb (Mvasi®, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
Pfizer's biosimilar (PF-06439535, trade name Zirabev®) received EMA marketing authorisation in April 2019, indicated for specified colorectal, breast, renal, lung, and cervical cancers.
SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882).
CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.

Database Links
Specialist databases
IMGT/mAb-DB	24
Other databases
GtoPdb PubChem SID	178103377
PubChem SID	178103377
Search PubMed clinical trials	bevacizumab
Search PubMed titles	bevacizumab
Search PubMed titles/abstracts	bevacizumab
Wikipedia	Bevacizumab